Cogent Biosciences (COGT) Expected to Release Earnings on Tuesday

Cogent Biosciences (NASDAQ:COGT) will likely be announcing its Q2 2026 results before the market opens on Tuesday, August 4th. Analysts expect the company to announce earnings of ($0.5550) per share and revenue of $0.0010 million for the quarter. Interested persons are encouraged to explore the company’s upcoming Q2 2026 earning results page for the latest details on the call scheduled for Wednesday, August 12, 2026 at 12:30 PM ET.

Cogent Biosciences (NASDAQ:COGT) last announced its quarterly earnings results on Tuesday, May 5th. The technology company reported ($0.53) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.53). On average, analysts expect Cogent Biosciences to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Cogent Biosciences Stock Performance

NASDAQ COGT opened at $38.93 on Monday. The company has a market cap of $6.65 billion, a price-to-earnings ratio of -17.94 and a beta of 0.38. Cogent Biosciences has a twelve month low of $10.38 and a twelve month high of $43.73. The company has a quick ratio of 15.14, a current ratio of 15.14 and a debt-to-equity ratio of 0.41. The business’s fifty day moving average is $36.66 and its 200 day moving average is $36.52.

Wall Street Analysts Forecast Growth

A number of research analysts recently issued reports on the stock. HC Wainwright raised their price objective on shares of Cogent Biosciences to $55.00 and gave the company a “buy” rating in a report on Wednesday, May 6th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Cogent Biosciences in a report on Wednesday, July 8th. Finally, Wedbush reiterated an “outperform” rating and issued a $55.00 target price on shares of Cogent Biosciences in a report on Friday, May 29th. Two investment analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $45.90.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of COGT. Deerfield Management Company L.P. increased its stake in Cogent Biosciences by 242.9% in the third quarter. Deerfield Management Company L.P. now owns 9,053,118 shares of the technology company’s stock valued at $130,003,000 after purchasing an additional 6,412,903 shares in the last quarter. RTW Investments LP increased its position in Cogent Biosciences by 119.0% in the 4th quarter. RTW Investments LP now owns 7,592,241 shares of the technology company’s stock valued at $269,676,000 after buying an additional 4,124,755 shares in the last quarter. State Street Corp raised its stake in Cogent Biosciences by 3.5% during the 4th quarter. State Street Corp now owns 4,940,300 shares of the technology company’s stock worth $175,479,000 after buying an additional 164,881 shares during the period. Janus Henderson Group PLC boosted its holdings in Cogent Biosciences by 42.8% in the fourth quarter. Janus Henderson Group PLC now owns 4,537,408 shares of the technology company’s stock worth $161,115,000 after acquiring an additional 1,359,365 shares in the last quarter. Finally, Vestal Point Capital LP increased its holdings in shares of Cogent Biosciences by 2.7% during the second quarter. Vestal Point Capital LP now owns 3,080,000 shares of the technology company’s stock valued at $22,114,000 after acquiring an additional 80,000 shares in the last quarter.

Cogent Biosciences Company Profile

Cogent Biosciences is a clinical-stage biopharmaceutical company focused on the discovery and development of small-molecule therapies that modulate the tumor microenvironment. The company’s research centers on targeting colony-stimulating factor 1 receptor (CSF1R), a key regulator of tumor-associated macrophages that can promote tumor growth and immune evasion. By selectively inhibiting CSF1R, Cogent Biosciences aims to restore immune surveillance and enhance the efficacy of existing cancer treatments.

The company’s lead asset is an orally bioavailable CSF1R inhibitor that has advanced into early-stage clinical trials for various solid tumors.